BACKGROUND: Nonfunctioning adrenal incidentalomas are common and many patients undergo adrenalectomy to exclude adrenocortical carcinoma (ACC). Recent studies have shown dysregulated microRNA (miRNA) expression in ACC. The objective of this study was to determine the feasibility and diagnostic accuracy of measuring serum miRNAs in patients with benign and malignant adrenocortical neoplasms. METHOD: Five miRNAs were selected from miRNA profiling studies in ACC (miR-let-7d, -34a, -195, -214, and 483-5p). Total miRNA was extracted from serum samples in patients with malignant and benign adrenal neoplasms. miRNAs levels were measured by quantitative reverse transcript polymerase chain reaction and normalized to miR-16. To determine if miRNAs were secreted from ACC cells, we measured miRNA levels in culture. RESULTS: Serum samples from 22 patients with cortical adenomas and 17 patients with ACC were analyzed, and all 5 miRNAs were detected. We found greater levels of miR-34a (P = .001) and miR-483-5p (P = .011) in patients with ACC. The area under the receiver operating characteristic curve was 0.81 for miR-34a and 0.74 for miR-438-5p. MiR-34a and miR-483-5p levels in ACC cells were greater in the supernatant at 48 hours compared with intracellular levels. CONCLUSION: We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. Published by Mosby, Inc.
BACKGROUND: Nonfunctioning adrenal incidentalomas are common and many patients undergo adrenalectomy to exclude adrenocortical carcinoma (ACC). Recent studies have shown dysregulated microRNA (miRNA) expression in ACC. The objective of this study was to determine the feasibility and diagnostic accuracy of measuring serum miRNAs in patients with benign and malignant adrenocortical neoplasms. METHOD: Five miRNAs were selected from miRNA profiling studies in ACC (miR-let-7d, -34a, -195, -214, and 483-5p). Total miRNA was extracted from serum samples in patients with malignant and benign adrenal neoplasms. miRNAs levels were measured by quantitative reverse transcript polymerase chain reaction and normalized to miR-16. To determine if miRNAs were secreted from ACC cells, we measured miRNA levels in culture. RESULTS: Serum samples from 22 patients with cortical adenomas and 17 patients with ACC were analyzed, and all 5 miRNAs were detected. We found greater levels of miR-34a (P = .001) and miR-483-5p (P = .011) in patients with ACC. The area under the receiver operating characteristic curve was 0.81 for miR-34a and 0.74 for miR-438-5p. MiR-34a and miR-483-5p levels in ACC cells were greater in the supernatant at 48 hours compared with intracellular levels. CONCLUSION: We show that dysregulated miRNAs in ACC are detectable in human serum samples. MiR-34a and miR-483-5p are candidate serum biomarkers for distinguishing between benign and malignant adrenocortical tumors. Published by Mosby, Inc.
Authors: P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye Journal: World J Surg Date: 2001-07 Impact factor: 3.352
Authors: Monika Piwecka; Katarzyna Rolle; Agnieszka Belter; Anna Maria Barciszewska; Marek Żywicki; Marcin Michalak; Stanisław Nowak; Mirosława Z Naskręt-Barciszewska; Jan Barciszewski Journal: Mol Oncol Date: 2015-03-25 Impact factor: 6.603
Authors: Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz Journal: Cell Mol Life Sci Date: 2014-10-09 Impact factor: 9.261
Authors: Zoltán Nagy; Kornélia Baghy; Éva Hunyadi-Gulyás; Tamás Micsik; Gábor Nyírő; Gergely Rácz; Henriett Butz; Pál Perge; Ilona Kovalszky; Katalin F Medzihradszky; Károly Rácz; Attila Patócs; Peter Igaz Journal: Am J Cancer Res Date: 2015-11-15 Impact factor: 6.166
Authors: Ivan Igaz; Gábor Nyírő; Zoltán Nagy; Henriett Butz; Zsolt Nagy; Pál Perge; Peter Sahin; Miklós Tóth; Károly Rácz; Peter Igaz; Attila Patócs Journal: Int J Endocrinol Date: 2015-06-16 Impact factor: 3.257